Concepedia

René Meisner

RM

Statistics

Publications

9

Citations

956

H-Index

9

Active since

2002

Affiliations

Denali Therapeutics (United States)(Current)

University of Minnesota

Biogen (United States)

René Meisner is an author at Denali Therapeutics (United States) specializing in pharmacology, life sciences, and neuroscience.

ORCID

Publications per year

2002–2025

9

Publications

9

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 252 citations

, , +17

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Wan-Ching Yen, Marcus Fischer, Fumiko Axelrod et al. · Clinical Cancer Research · 2015 · 241 citations

, , +14

Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic

Todd Logan, Matthew Simon, Gerald Maxwell Cherf et al. · Cell · 2021 · 229 citations · Full text

, , +12

CD98hc is a target for brain delivery of biotherapeutics

Kylie S. Chew, Robert C. Wells, Arash Moshkforoush et al. · Nature Communications · 2023 · 88 citations · Full text

, , +17

The Ubiquitin-Conjugating Enzyme E2-EPF Is Overexpressed in Primary Breast Cancer and Modulates Sensitivity to Topoisomerase II Inhibition

Donato Tedesco, Jianhua Zhang, Lan Trinht et al. · Neoplasia · 2007 · 49 citations · Full text

, , +16

1–5 of 9